LTBR acts as a novel immune checkpoint of tumor-associated macrophages for cancer immunotherapy

Abstract

Tumor-associated macrophages (TAMs) greatly contribute to immune checkpoint inhibitor (ICI) resistance of cancer. However, its underlying mechanisms and whether TAMs can be promising targets to overcome ICI resistance remain to be unveiled. Through integrative analysis of immune multiomics data and single-cell RNA-seq data (iMOS) in lung adenocarcinoma (LUAD), lymphotoxin β receptor (LTBR) is identified as a potential immune checkpoint of TAMs, whose high expression, duplication, and low methylation are correlated with unfavorable prognosis. Immunofluorescence staining shows that the infiltration of LTBR⁺ TAMs is associated with LUAD stages, immunotherapy failure, and poor prognosis. Mechanistically, LTΒR maintains immunosuppressive activity and M2 phenotype of TAMs by noncanonical nuclear factor kappa B and Wnt/β-catenin signaling pathways. Macrophage-specific knockout of LTBR hinders tumor growth and prolongs survival time via blocking TAM immunosuppressive activity and M2 phenotype. Moreover, TAM-targeted delivery of LTΒR small interfering RNA improves the therapeutic effect of ICI via reversing TAM-mediated immunosuppression, such as boosting cytotoxic CD8⁺ T cells and inhibiting granulocytic myeloid-derived suppressor cells infiltration. Taken together, we bring forth an immune checkpoint discovery pipeline iMOS, identify LTBR as a novel immune checkpoint of TAMs, and propose a new immunotherapy strategy by targeting LTBR⁺ TAMs.

Keywords

immune checkpoint / LTBR / myeloid derived suppressor cells / CD8⁺ T cells / tumor-associated macrophages

References

[1] Shi, Jianxin, Xing Hua, Bin Zhu, Sarangan Ravichandran, Mingyi Wang, Cu Nguyen, Seth A. Brodie, et al. 2016. “Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.” PLoS Medicine 13: e1002162. https://doi.org/10.1371/journal.pmed.1002162

[2] Forde, Patrick M., Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, et al. 2022. “Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer.” New England Journal of Medicine 386: 1973-1985. https://doi.org/10.1056/NEJMoa2202170

[3] Lei, Jie, Jinbo Zhao, Li Gong, Yunfeng Ni, Yongan Zhou, Feng Tian, Honggang Liu, et al. 2023. “Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.” JAMA Oncology 9: 1348-1355. https://doi.org/10.1001/jamaoncol.2023.2751

[4] Vokes, Natalie I., Kelsey Pan, and Xiuning Le. 2023. “Efficacy of Immunotherapy in Oncogene-Driven Non-Small-Cell Lung Cancer.” Therapeutic Advances in Medical Oncology 15: 17588359231161409. https://doi.org/10.1177/17588359231161409

[5] Herbst, Roy S., Daniel Morgensztern, and Chris Boshoff. 2018. “The Biology and Management of Non-Small Cell Lung Cancer.” Nature 553: 446-454. https://doi.org/10.1038/nature25183

[6] Chong, Wei, Huicheng Ren, Hao Chen, Kang Xu, Xingyu Zhu, Yuan Liu, Yaodong Sang, et al. 2024. “Clinical Features and Molecular Landscape of Cuproptosis Signature-Related Molecular Subtype in Gastric Cancer.” iMeta 3: e190. https://doi.org/10.1002/imt2.190

[7] Sun, Xiwei, Jiani Yi, Juze Yang, Yi Han, Xinyi Qian, Yi Liu, Jia Li, et al. 2021. “An Integrated Epigenomic-Transcriptomic Landscape of Lung Cancer Reveals Novel Methylation Driver Genes of Diagnostic and Therapeutic Relevance.” Theranostics 11: 5346-5364. https://doi.org/10.7150/thno.58385

[8] Wu, Quanyou, Lin Feng, Yaru Wang, Yousheng Mao, Xuebing Di, Kaitai Zhang, Shujun Cheng, and Ting Xiao. 2022. “Multi-Omics Analysis Reveals RNA Splicing Alterations and Their Biological and Clinical Implications in Lung Adenocarcinoma.” Signal Transduction and Targeted Therapy 7: 270. https://doi.org/10.1038/s41392-022-01098-5

[9] Meng, Jialin, Aimin Jiang, Xiaofan Lu, Di Gu, Qintao Ge, Suwen Bai, Yundong Zhou, et al. 2023. “Multiomics Characterization and Verification of Clear Cell Renal Cell Carcinoma Molecular Subtypes to Guide Precise Chemotherapy and Immunotherapy.” iMeta 2: e147. https://doi.org/10.1002/imt2.147

[10] DeNardo, David G., and Brian Ruffell. 2019. “Macrophages as Regulators of Tumour Immunity and Immunotherapy.” Nature Reviews Immunology 19: 369-382. https://doi.org/10.1038/s41577-019-0127-6

[11] Pathria, Paulina, Tiani L. Louis, and Judith A. Varner. 2019. “Targeting Tumor-Associated Macrophages in Cancer.” Trends in Immunology 40: 310-327. https://doi.org/10.1016/j.it.2019.02.003

[12] Lee, Alexander H., Lu Sun, Aaron Y. Mochizuki, Jeremy G. Reynoso, Joey Orpilla, Frances Chow, Jenny C. Kienzler, et al. 2021. “Neoadjuvant PD-1 Blockade Induces T Cell and cDC1 Activation But Fails to Overcome the Immunosuppressive Tumor Associated Macrophages in Recurrent Glioblastoma.” Nature Communications 12: 6938. https://doi.org/10.1038/s41467-021-26940-2

[13] Wolf, M. J., G. M. Seleznik, N. Zeller, and M. Heikenwalder. 2010. “The Unexpected Role of Lymphotoxin β Receptor Signaling in Carcinogenesis: From Lymphoid Tissue Formation to Liver and Prostate Cancer Development.” Oncogene 29: 5006-5018. https://doi.org/10.1038/onc.2010.260

[14] Ware, C. F., P. D. Crowe, M. H. Grayson, M. J. Androlewicz, and J. L. Browning. 1992. “Expression of Surface Lymphotoxin and Tumor Necrosis Factor on Activated T, B, and Natural Killer Cells.” The Journal of Immunology 149: 3881-3888. https://doi.org/10.4049/jimmunol.149.12.3881https://www.ncbi.nlm.nih.gov/pubmed/1281193

[15] Mauri, Davide N., Reinhard Ebner, Rebecca I. Montgomery, Kristine D. Kochel, Timothy C. Cheung, Guo-Liang Yu, Steve Ruben, et al. 1998. “LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin α Are Ligands for Herpesvirus Entry Mediator.” Immunity 8: 21-30. https://doi.org/10.1016/s1074-7613(00)80455-0

[16] Remouchamps, Caroline, Layla Boutaffala, Corinne Ganeff, and Emmanuel Dejardin. 2011. “Biology and Signal Transduction Pathways of the Lymphotoxin-Alphabeta/LTbetaR System.” Cytokine & Growth Factor Reviews 22: 301-310. https://doi.org/10.1016/j.cytogfr.2011.11.007

[17] Camara, Abdouramane, Alice C. Lavanant, Jun Abe, Henri Lee Desforges, Yannick O. Alexandre, Erika Girardi, Zinaida Igamberdieva, et al. 2022. “CD169⁺ Macrophages in Lymph Node and Spleen Critically Depend on Dual RANK and LTbetaR Signaling.” Proceedings of the National Academy of Sciences of the United States of America 119: e2108540119. https://doi.org/10.1073/pnas.2108540119

[18] Wimmer, Nadin, Barbara Huber, Nicola Barabas, Johann Röhrl, Klaus Pfeffer, and Thomas Hehlgans. 2012. “Lymphotoxin β Receptor Activation on Macrophages Induces Cross-Tolerance to TLR4 and TLR9 Ligands.” The Journal of Immunology 188: 3426-3433. https://doi.org/10.4049/jimmunol.1103324

[19] Yoshihara, Kosuke, Maria Shahmoradgoli, Emmanuel Martínez, Rahulsimham Vegesna, Hoon Kim, Wandaliz Torres-Garcia, Victor Treviño, et al. 2013. “Inferring Tumour Purity and Stromal and Immune Cell Admixture From Expression Data.” Nature Communications 4: 2612. https://doi.org/10.1038/ncomms3612

[20] Lee, Eung-Sirk, Dae-Soon Son, Sung-Hyun Kim, Jinseon Lee, Jisuk Jo, Joungho Han, Heesue Kim, et al. 2008. “Prediction of Recurrence-Free Survival in Postoperative Non-Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression.” Clinical Cancer Research 14: 7397-7404. https://doi.org/10.1158/1078-0432.CCR-07-4937

[21] Tomida, Shuta, Toshiyuki Takeuchi, Yukako Shimada, Chinatsu Arima, Keitaro Matsuo, Tetsuya Mitsudomi, Yasushi Yatabe, and Takashi Takahashi. 2009. “Relapse-Related Molecular Signature in Lung Adenocarcinomas Identifies Patients With Dismal Prognosis.” Journal of Clinical Oncology 27: 2793-2799. https://doi.org/10.1200/JCO.2008.19.7053

[22] Feng, Lin, Jiamei Wang, Bangrong Cao, Yi Zhang, Bo Wu, Xuebing Di, Wei Jiang, et al. 2014. “Gene Expression Profiling in Human Lung Development: An Abundant Resource for Lung Adenocarcinoma Prognosis.” PLoS One 9: e105639. https://doi.org/10.1371/journal.pone.0105639

[23] Shedden, Kerby, Jeremy M. G. Taylor, Steven A. Enkemann, Ming-Sound Tsao, Timothy J. Yeatman, William L. Gerald, Steven Eschrich, et al. 2008. “Gene Expression-Based Survival Prediction in Lung Adenocarcinoma: A Multi-Site, Blinded Validation Study.” Nature Medicine 14: 822-827. https://doi.org/10.1038/nm.1790

[24] Ruf, Benjamin, Matthias Bruhns, Sepideh Babaei, Noemi Kedei, Lichun Ma, Mahler Revsine, Mohamed-Reda Benmebarek, et al. 2023. “Tumor-Associated Macrophages Trigger MAIT Cell Dysfunction at the HCC Invasive Margin.” Cell 186: 3686-3705.e32. https://doi.org/10.1016/j.cell.2023.07.026

[25] Zhang, Hao, Lin Liu, Jinbo Liu, Pengyuan Dang, Shengyun Hu, Weitang Yuan, Zhenqiang Sun, Yang Liu, and Chengzeng Wang. 2023. “Roles of Tumor-Associated Macrophages in Anti-PD-1/PD-L1 Immunotherapy for Solid Cancers.” Molecular Cancer 22: 58. https://doi.org/10.1186/s12943-023-01725-x

[26] Wu, Yuze, Ming Yi, Mengke Niu, Qi Mei, and Kongming Wu. 2022. “Myeloid-Derived Suppressor Cells: An Emerging Target for Anticancer Immunotherapy.” Molecular Cancer 21: 184. https://doi.org/10.1186/s12943-022-01657-y

[27] Ozbay Kurt, Feyza Gul, Samantha Lasser, Ihor Arkhypov, Jochen Utikal, and Viktor Umansky. 2023. “Enhancing Immunotherapy Response in Melanoma: Myeloid-Derived Suppressor Cells as a Therapeutic Target.” Journal of Clinical Investigation 133: e170762. https://doi.org/10.1172/JCI170762

[28] Cassetta, Luca, and Jeffrey W. Pollard. 2018. “Targeting Macrophages: Therapeutic Approaches in Cancer.” Nature Reviews Drug Discovery 17: 887-904. https://doi.org/10.1038/nrd.2018.169

[29] Jaillon, Sebastien, Andrea Ponzetta, Diletta Di Mitri, Angela Santoni, Raffaella Bonecchi, and Alberto Mantovani. 2020. “Neutrophil Diversity and Plasticity in Tumour Progression and Therapy.” Nature Reviews Cancer 20: 485-503. https://doi.org/10.1038/s41568-020-0281-y

[30] Mantovani, Alberto, Federica Marchesi, Alberto Malesci, Luigi Laghi, and Paola Allavena. 2017. “Tumour-Associated Macrophages as Treatment Targets in Oncology.” Nature Reviews Clinical Oncology 14: 399-416. https://doi.org/10.1038/nrclinonc.2016.217

[31] Wherry, E John, and Makoto Kurachi. 2015. “Molecular and Cellular Insights into T Cell Exhaustion.” Nature Reviews Immunology 15: 486-499. https://doi.org/10.1038/nri3862

[32] Andrews, Lawrence P., Hiroshi Yano, and Dario A. A. Vignali. 2019. “Inhibitory Receptors and Ligands Beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or Backups.” Nature Immunology 20: 1425-1434. https://doi.org/10.1038/s41590-019-0512-0

[33] Dejardin, Emmanuel, Nathalie M. Droin, Mireille Delhase, Elvira Haas, Yixue Cao, Constantin Makris, Zhi-Wei Li, et al. 2002. “The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression Via Two NF-κB Pathways.” Immunity 17: 525-535. https://doi.org/10.1016/s1074-7613(02)00423-5

[34] Qin, Hualong, Jun Zhou, Jingjing Xu, Li Cheng, Zaixiang Tang, Haitao Ma, and Feng Guo. 2018. “The Nuclear Transcription Factor RelB Functions as an Oncogene in Human Lung Adenocarcinoma SPC-A1 Cells.” Cancer Cell International 18: 88. https://doi.org/10.1186/s12935-018-0580-5

[35] Stewart, David J. 2014. “Wnt Signaling Pathway in Non-Small Cell Lung Cancer.” JNCI Journal of the National Cancer Institute 106: djt356. https://doi.org/10.1093/jnci/djt356

[36] Yang, Yang, Yu-Chen Ye, Yan Chen, Jun-Long Zhao, Chun-Chen Gao, Hua Han, Wen-Chao Liu, and Hong-Yan Qin. 2018. “Crosstalk Between Hepatic Tumor Cells and Macrophages Via Wnt/Beta-Catenin Signaling Promotes M2-Like Macrophage Polarization and Reinforces Tumor Malignant Behaviors.” Cell Death & Disease 9: 793. https://doi.org/10.1038/s41419-018-0818-0

[37] Kaneda, Megan M., Karen S. Messer, Natacha Ralainirina, Hongying Li, Christopher J. Leem, Sara Gorjestani, Gyunghwi Woo, et al. 2016. “PI3Kγ Is a Molecular Switch That Controls Immune Suppression.” Nature 539: 437-442. https://doi.org/10.1038/nature19834

[38] Wang, Liang, Yi-Yang Hu, Jun-Long Zhao, Fei Huang, Shi-Qian Liang, Lei Dong, Yan Chen, et al. 2020. “Targeted Delivery of miR-99b Reprograms Tumor-Associated Macrophage Phenotype Leading to Tumor Regression.” Journal for Immunotherapy of Cancer 8: e000517. https://doi.org/10.1136/jitc-2019-000517

[39] Gillette, Michael A., Shankha Satpathy, Song Cao, Saravana M. Dhanasekaran, Suhas V. Vasaikar, Karsten Krug, Francesca Petralia, et al. 2020. “Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.” Cell 182: 200-225e235. https://doi.org/10.1016/j.cell.2020.06.013

[40] Zilionis, Rapolas, Camilla Engblom, Christina Pfirschke, Virginia Savova, David Zemmour, Hatice D. Saatcioglu, Indira Krishnan, et al. 2019. “Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations Across Individuals and Species.” Immunity 50: 1317-1334.e10. https://doi.org/10.1016/j.immuni.2019.03.009

[41] Shuptrine, Casey W., Vincent M. Perez, Sara R. Selitsky, Taylor H. Schreiber, and George Fromm. 2023. “Shining a LIGHT on Myeloid Cell Targeted Immunotherapy.” European Journal of Cancer 187: 147-160. https://doi.org/10.1016/j.ejca.2023.03.040

[42] Sagiv, Jitka Y., Janna Michaeli, Simaan Assi, Inbal Mishalian, Hen Kisos, Liran Levy, Pazzit Damti, et al. 2015. “Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer.” Cell Reports 10: 562-573. https://doi.org/10.1016/j.celrep.2014.12.039

[43] Zhang, Xian, Liangliang Ji, and Ming O. Li. 2023. “Control of Tumor-Associated Macrophage Responses by Nutrient Acquisition and Metabolism.” Immunity 56: 14-31. https://doi.org/10.1016/j.immuni.2022.12.003

[44] Smith, Logan K., Giselle M. Boukhaled, Stephanie A. Condotta, Sabrina Mazouz, Jenna J. Guthmiller, Rahul Vijay, Noah S. Butler, et al. 2018. “Interleukin-10 Directly Inhibits CD8⁺ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity.” Immunity 48: 299-312.e5. https://doi.org/10.1016/j.immuni.2018.01.006

[45] Mariathasan, Sanjeev, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E. Kadel,, et al. 2018. “TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells.” Nature 554: 544-548. https://doi.org/10.1038/nature25501

[46] Zhang, Baochun, Dinis Pedro Calado, Zhe Wang, Sebastian Fröhler, Karl Köchert, Yu Qian, Sergei B. Koralov, et al. 2015. “An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed Upon Deregulated BCL6 Expression.” Cell Reports 11: 715-726. https://doi.org/10.1016/j.celrep.2015.03.059

[47] Cildir, Gökhan, Kee Chung Low, and Vinay Tergaonkar. 2016. “Noncanonical NF-κB Signaling in Health and Disease.” Trends in Molecular Medicine 22: 414-429. https://doi.org/10.1016/j.molmed.2016.03.002

[48] Moy, Ryan H., Alexander Nguyen, Jia Min Loo, Norihiro Yamaguchi, Christina M. Kajba, Balaji Santhanam, Benjamin N. Ostendorf, et al. 2022. “Functional Genetic Screen Identifies ITPR3/Calcium/RELB Axis as a Driver of Colorectal Cancer Metastatic Liver Colonization.” Developmental Cell 57: 1146-1159.e7. https://doi.org/10.1016/j.devcel.2022.04.010

[49] Lim, Shen Kiat, Chen Chen Peng, Shannon Low, Varsheni Vijay, Andrea Budiman, Beng Hooi Phang, Jing Quan Lim, et al. 2023. “Sustained Activation of Non-Canonical NF-κB Signalling Drives Glycolytic Reprogramming in Doxorubicin-Resistant DLBCL.” Leukemia 37: 441-452. https://doi.org/10.1038/s41375-022-01769-w

[50] De Paolis, Veronica, Fabio Maiullari, Maila Chirivì, Marika Milan, Chiara Cordiglieri, Francesca Pagano, Alessandra Rita La Manna, et al. 2022. “Unusual Association of NF-κB Components in Tumor-Associated Macrophages (TAMs) Promotes HSPG2-Mediated Immune-Escaping Mechanism in Breast Cancer.” International Journal of Molecular Sciences 23: 7902. https://doi.org/10.3390/ijms23147902

[51] Ye, Yu-Chen, Jun-Long Zhao, Yi-Tong Lu, Chun-Chen Gao, Yang Yang, Shi-Qian Liang, Ying-Ying Lu, et al. 2019. “NOTCH Signaling Via WNT Regulates the Proliferation of Alternative, CCR2-Independent Tumor-Associated Macrophages in Hepatocellular Carcinoma.” Cancer Research 79: 4160-4172. https://doi.org/10.1158/0008-5472.CAN-18-1691

[52] Sarode, Poonam, Xiang Zheng, Georgia A. Giotopoulou, Andreas Weigert, Carste Kuenne, Stefan Günther, Aleksandra Friedrich, et al. 2020. “Reprogramming of Tumor-Associated Macrophages by Targeting β-Catenin/FOSL2/ARID5A Signaling: A Potential Treatment of Lung Cancer.” Science Advances 6: eaaz6105. https://doi.org/10.1126/sciadv.aaz6105

[53] Yu, Fanyuan, Changhao Yu, Feifei Li, Yanqin Zuo, Yitian Wang, Lin Yao, Chenzhou Wu, Chenglin Wang, and Ling Ye. 2021. “Wnt/β-Catenin Signaling in Cancers and Targeted Therapies.” Signal Transduction and Targeted Therapy 6: 307. https://doi.org/10.1038/s41392-021-00701-5

[54] Liu, Jiaqi, Qing Xiao, Jiani Xiao, Chenxi Niu, Yuanyuan Li, Xiaojun Zhang, Zhengwei Zhou, Guang Shu, and Gang Yin. 2022. “Wnt/β-Catenin Signalling: Function, Biological Mechanisms, and Therapeutic Opportunities.” Signal Transduction and Targeted Therapy 7: 3. https://doi.org/10.1038/s41392-021-00762-6

[55] Weiskopf, Kipp. 2017. “Cancer Immunotherapy Targeting the CD47/SIRPα Axis.” European Journal of Cancer 76: 100-109. https://doi.org/10.1016/j.ejca.2017.02.013

[56] Hume, David A., and Kelli P. A. MacDonald. 2012. “Therapeutic Applications of Macrophage Colony-Stimulating Factor-1 (CSF-1) and Antagonists of CSF-1 Receptor (CSF-1R) Signaling.” Blood 119: 1810-1820. https://doi.org/10.1182/blood-2011-09-379214

[57] Oldenborg, Per-Arne, Alex Zheleznyak, Yi-Fu Fang, Carl F. Lagenaur, Hattie D. Gresham, and Frederik P. Lindberg. 2000. “Role of CD47 as a Marker of Self on Red Blood Cells.” Science 288: 2051-2054. https://doi.org/10.1126/science.288.5473.2051

[58] Oldenborg, Per-Arne, Hattie D. Gresham, Yongmei Chen, Shozo Izui, and Frederik P. Lindberg. 2002. “Lethal Autoimmune Hemolytic Anemia in CD47-Deficient Nonobese Diabetic (NOD) Mice.” Blood 99: 3500-3504. https://doi.org/10.1182/blood.v99.10.3500

[59] Zhao, Jun-Long, Yu-Chen Ye, Chun-Chen Gao, Liang Wang, Kai-Xi Ren, Ru Jiang, Si-Jun Hu, et al. 2022. “Notch-Mediated Lactate Metabolism Regulates MDSC Development Through the Hes1/MCT2/c-Jun Axis.” Cell Reports 38: 110451. https://doi.org/10.1016/j.celrep.2022.110451

[60] Liu, Jianfang, Tara Lichtenberg, Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich, et al. 2018. “An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.” Cell 173: 400-416.e11. https://doi.org/10.1016/j.cell.2018.02.052

[61] Liu, Chun-Jie, Fei-Fei Hu, Gui-Yan Xie, Ya-Ru Miao, Xin-Wen Li, Yan Zeng, and An-Yuan Guo. 2023. “GSCA: An Integrated Platform for Gene Set Cancer Analysis at Genomic, Pharmacogenomic and Immunogenomic Levels.” Briefings in Bioinformatics 24: bbac558. https://doi.org/10.1093/bib/bbac558

[62] Gu, Zuguang. 2022. “Complex Heatmap Visualization.” iMeta 1: e43. https://doi.org/10.1002/imt2.43

[63] Wolf, F. Alexander, Philipp Angerer, and Fabian J. Theis. 2018. “SCANPY: Large-Scale Single-Cell Gene Expression Data Analysis.” Genome Biology 19: 15. https://doi.org/10.1186/s13059-017-1382-0

[64] Xu, Limin, Jing Zhang, Yiqian He, Qianqian Yang, Tianhao Mu, Qiushi Guo, Yingqiang Li, et al. 2023. “ScRNAPip: A Systematic and Dynamic Pipeline for Single-Cell RNA Sequencing Analysis.” iMeta 2: e132. https://doi.org/10.1002/imt2.132

[65] Wang, Guoliang, Song Wu, Zhuang Xiong, Hongzhu Qu, Xiangdong Fang, and Yiming Bao. 2024 CROST: A Comprehensive Repository of Spatial Transcriptomics.” Nucleic Acids Research 52: D882-D890. https://doi.org/10.1093/nar/gkad782

[66] Dobin, Alexander, Carrie A. Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali Jha, Philippe Batut, Mark Chaisson, and Thomas R. Gingeras. 2013. “STAR: Ultrafast Universal RNA-Seq Aligner.” Bioinformatics (Oxford, England) 29: 15-21. https://doi.org/10.1093/bioinformatics/bts635

[67] Fawkner-Corbett, David, Agne Antanaviciute, Kaushal Parikh, Marta Jagielowicz, Ana Sousa Gerós, Tarun Gupta, Neil Ashley, et al. 2021. “Spatiotemporal Analysis of Human Intestinal Development at Single-Cell Resolution.” Cell 184: 810-826.e23. https://doi.org/10.1016/j.cell.2020.12.016

[68] Liu, Tao, Jorge A. Ortiz, Len Taing, Clifford A. Meyer, Bernett Lee, Yong Zhang, Hyunjin Shin, et al. 2011. “Cistrome: An Integrative Platform for Transcriptional Regulation Studies.” Genome Biology 12: R83. https://doi.org/10.1186/gb-2011-12-8-r83

[69] Cao, Tianyu, Wenyao Zhang, Qi Wang, Chen Wang, Wanqi Ma, Cangang Zhang, Minghui Ge, et al. 2024. “Cancer SLC6A6-Mediated Taurine Uptake Transactivates Immune Checkpoint Genes and Induces Exhaustion in CD8⁺ T Cells.” Cell 187: 2288-2304.e27. https://doi.org/10.1016/j.cell.2024.03.011

[70] Huang, Zhen, Zhengping Zhang, Yucui Jiang, Dachuan Zhang, Jiangning Chen, Lei Dong, and Junfeng Zhang. 2012. “Targeted Delivery of Oligonucleotides into Tumor-Associated Macrophages for Cancer Immunotherapy.” Journal of Controlled Release 158: 286-292. https://doi.org/10.1016/j.jconrel.2011.11.013

[71] Huang, Zhen, Jingjing Gan, Ziyan Long, Guangxing Guo, Xiafei Shi, Chunming Wang, Yuhui Zang, et al. 2016. “Targeted Delivery of Iet-7b to Reprogramme Tumor-Associated Macrophages and Tumor Infiltrating Dendritic Cells for Tumor Rejection.” Biomaterials 90: 72-84. https://doi.org/10.1016/j.biomaterials.2016.03.009

RIGHTS & PERMISSIONS

2024 The Author(s). iMeta published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science.